betamethasone

(redirected from Betamethasone dipropionate)
Also found in: Medical, Encyclopedia.

be·ta·meth·a·sone

 (bā′tə-mĕth′ə-sōn′, bē′-)
n.
A synthetic glucocorticoid, C22H29FO5, that occurs as a white crystalline powder and is used as a topical anti-inflammatory agent for the treatment of dermatological conditions.

[Shortening of betadexamethasone : beta- + dexamethasone.]
Translations

betamethasone

n betametasona
References in periodicals archive ?
Release date- 07082019 - Copenhagen - MC2 Therapeutics A/S, a late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions, today announced the completion of enrollment for its EU Phase 3 study assessing the safety and efficacy of MC2-01 PAD Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in adult patients with plaque psoriasis compared to Daivobet gel (marketed in the US as Taclonex Topical Suspension).
- The US Food and Drug Administration has expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older, US-based medical dermatology company Leo Pharma Inc., a wholly owned subsidiary of Denmark-based Leo Pharma A/S, said.
For example, betamethasone dipropionate 0.05% in an ointment is considered a class I super potent steroid, whereas the same ingredient at the same concentration in a spray is a class III steroid.
Betamethasone dipropionate 0.025 % w/w, neomycin 0.5 % w/w,
TABLE Topical corticosteroids of varying potency that can be considered for treating lichen sclerosus Potency Corticosteroid ointment Very high Clobetasol propionate 0.05$ Betamethasone dipropionate 0.05% High Mometasone furoate 0.1% Moderate Triamcinolone 0.1% Low Hydrocortisone 1%
Despite more aggressive treatment with fluocinonide 0.05% ointment twice daily, alternated with tacrolimus 0.03% ointment, and later augmented with betamethasone dipropionate 0.05% ointment twice daily from frequent flares, relief was not achieved.
Therefore, the present study was carried out to compare the effectiveness of calcipotriol versus betamethasone dipropionate in the treatment of mild to moderate chronic plaque psoriasis.
These include calcipotriol combined with betamethasone dipropionate, phototherapy, topical immunomodulators like tacrolimus; Imiquimod, systemic steroids combined with methotrexate, cyclosporine, mycophenolate mofetil, D-penicillamine, photopheresis etc.5,6
However, 1 mL of this preparation contains a lower dose of the rapid-acting compound betamethasone sodium phosphate and a higher dose of the long-acting compound betamethasone dipropionate. This difference in composition might have a different effect on blood glucose levels.
Topical calcipotriol/betamethasone dipropionate is a yellow-to-white substance including 50 [micro]g/g calcipotriol and 500 [micro]g/g betamethasone dipropionate. Calcipotriol is a vitamin D derivative and acts similar to vitamin D, making a reversible temperature-dependent equilibrium between calcipotriol and precalcipotriol.
He is a known case of generalised pustular psoriasis for 8-year duration maintained on daily topical calcipotriol, a vitamin D derivative, and intermittent use of topical betamethasone dipropionate during flare-ups.